Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Core Viewpoint - Corvus Pharmaceuticals, Inc. is set to provide a business update and report its fourth quarter 2025 financial results during a conference call on March 12, 2026 [1]. Group 1: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel approach to immunotherapy for various immune diseases and cancers [3]. - The company's lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK [3]. - Soquelitinib is currently being evaluated in a registration Phase 3 clinical trial for relapsed/refractory peripheral T-cell lymphoma (PTCL) and in a Phase 1 clinical trial for atopic dermatitis [3]. - Other clinical-stage candidates are being developed for multiple cancer indications [3]. Group 2: Conference Call Details - The conference call will take place on March 12, 2026, at 4:30 pm ET (1:30 pm PT) [1]. - Access to the conference call can be made via a toll-free domestic number or an international number, as well as through a link for instant telephone access [2]. - A live webcast will be available on the investor relations section of the Corvus website, with a replay accessible for 90 days [2].